Innovive Pharmaceuticals Licenses Growth Factor From PSU

March 17, 2005

Innovive Pharmaceuticals, a biopharmaceutical company headquartered in Manhattan, announced it has licensed worldwide rights for the use of Opioid Growth Factor (OGF) in oncology from Penn State. OGF, also known as (Met5)-enkephalin, is a naturally occurring molecule found in the human body that has recently been shown to significantly reduce the proliferation of pancreatic cancer cells. OGF will be developed under the name INNO-105.

Yahoo News (http://biz.yahoo.com/bw/050317/175398_1.html)